Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Geron Corporation stock logo
GERN
Geron
$1.45
-2.0%
$1.32
$1.04
$2.01
$949.45M0.68.03 million shs5.02 million shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$2.34
+4.9%
$2.17
$1.00
$2.68
$990.56M1.052.71 million shs2.68 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.65
+33.1%
$1.38
$0.98
$1.73
$936.31M1.482.61 million shs34.53 million shs
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$3.45
+0.3%
$3.69
$1.85
$5.15
$263.04M0.52511,559 shs241,299 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Geron Corporation stock logo
GERN
Geron
-2.03%+0.69%+10.27%-3.97%+26.09%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
+4.93%-1.68%-8.24%+50.97%+114.68%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+33.06%+36.36%+7.84%+48.65%+22.22%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
+0.29%-5.22%-9.21%-0.86%+36.36%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Geron Corporation stock logo
GERN
Geron
$1.45
-2.0%
$1.32
$1.04
$2.01
$949.45M0.68.03 million shs5.02 million shs
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$2.34
+4.9%
$2.17
$1.00
$2.68
$990.56M1.052.71 million shs2.68 million shs
OPKO Health, Inc. stock logo
OPK
OPKO Health
$1.65
+33.1%
$1.38
$0.98
$1.73
$936.31M1.482.61 million shs34.53 million shs
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$3.45
+0.3%
$3.69
$1.85
$5.15
$263.04M0.52511,559 shs241,299 shs
7 Stocks to Buy Before the Robotics Revolution Cover

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries.

"Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Geron Corporation stock logo
GERN
Geron
-2.03%+0.69%+10.27%-3.97%+26.09%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
+4.93%-1.68%-8.24%+50.97%+114.68%
OPKO Health, Inc. stock logo
OPK
OPKO Health
+33.06%+36.36%+7.84%+48.65%+22.22%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
+0.29%-5.22%-9.21%-0.86%+36.36%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Geron Corporation stock logo
GERN
Geron
2.20
Hold$4.00175.86% Upside
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
2.75
Moderate Buy$4.5594.44% Upside
OPKO Health, Inc. stock logo
OPK
OPKO Health
1.80
Reduce$1.55-6.06% Downside
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
2.73
Moderate Buy$12.00247.83% Upside

Current Analyst Ratings Breakdown

Latest SABS, LXRX, GERN, and OPK Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/24/2026
Geron Corporation stock logo
GERN
Geron
DowngradeSell (D-)Sell (E+)
7/23/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
UpgradeSell (E+)Sell (D-)
7/9/2026
Geron Corporation stock logo
GERN
Geron
UpgradeSell (E+)Sell (D-)
7/8/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
DowngradeSell (D-)Sell (E+)
7/8/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Reiterated RatingSell (D+)
7/3/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
UpgradeHoldStrong-Buy
6/24/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Initiated CoverageOverweight$13.00
6/23/2026
Geron Corporation stock logo
GERN
Geron
DowngradeSell (D-)Sell (E+)
6/18/2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
Reiterated RatingSell (D-)
6/17/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Boost Price TargetBuy$14.00 ➝ $16.00
6/15/2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
Boost Price TargetOutperform$7.00 ➝ $12.00
(Data available from 7/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Geron Corporation stock logo
GERN
Geron
$183.88M5.06N/AN/A$0.35 per share4.14
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
$49.80M20.87N/AN/A$0.30 per share7.80
OPKO Health, Inc. stock logo
OPK
OPKO Health
$606.90M2.05N/AN/A$1.67 per share0.99
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$1.32M199.84$0.34 per share10.07$3.18 per share1.08
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Geron Corporation stock logo
GERN
Geron
-$83.50M-$0.11N/A16.11N/A-35.48%-23.31%-10.08%8/5/2026 (Estimated)
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$50.34M-$0.07N/AN/AN/A-37.46%-18.64%-11.79%8/5/2026 (Estimated)
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$225.68M-$0.27N/AN/AN/A-12.40%-5.79%-3.78%N/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
$13.27M-$2.11N/AN/AN/AN/A-0.29%-0.25%8/6/2026 (Estimated)

Latest SABS, LXRX, GERN, and OPK Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$0.29N/AN/AN/A$0.13 millionN/A
8/5/2026Q2 2026
Geron Corporation stock logo
GERN
Geron
-$0.01N/AN/AN/A$55.30 millionN/A
8/5/2026Q2 2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.06N/AN/AN/A$3.99 millionN/A
7/27/2026Q2 2026
OPKO Health, Inc. stock logo
OPK
OPKO Health
-$0.08-$0.01+$0.07-$0.01$131.23 million$163.58 million
5/12/2026Q1 2026
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
-$0.20-$0.35-$0.15-$0.35$0.13 millionN/A
5/7/2026Q1 2026
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
-$0.04-$0.0026+$0.0374N/A$9.79 million$21.10 million
5/6/2026Q1 2026
Geron Corporation stock logo
GERN
Geron
-$0.03-$0.01+$0.02-$0.01$50.59 million$51.84 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Geron Corporation stock logo
GERN
Geron
N/AN/AN/AN/AN/A
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
N/AN/AN/AN/AN/A
OPKO Health, Inc. stock logo
OPK
OPKO Health
N/AN/AN/AN/AN/A
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Geron Corporation stock logo
GERN
Geron
0.52
6.78
4.96
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
0.24
18.80
18.77
OPKO Health, Inc. stock logo
OPK
OPKO Health
0.28
3.61
3.17
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
0.01
11.45
11.45

Institutional Ownership

CompanyInstitutional Ownership
Geron Corporation stock logo
GERN
Geron
73.71%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
74.70%
OPKO Health, Inc. stock logo
OPK
OPKO Health
64.63%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
7.82%

Insider Ownership

CompanyInsider Ownership
Geron Corporation stock logo
GERN
Geron
1.71%
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
14.00%
OPKO Health, Inc. stock logo
OPK
OPKO Health
44.72%
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
7.39%
CompanyEmployeesShares OutstandingFree FloatOptionable
Geron Corporation stock logo
GERN
Geron
70641.52 million630.55 millionOptionable
Lexicon Pharmaceuticals, Inc. stock logo
LXRX
Lexicon Pharmaceuticals
140444.20 million382.01 millionOptionable
OPKO Health, Inc. stock logo
OPK
OPKO Health
1,373755.09 million417.42 millionOptionable
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
14076.46 million70.81 millionNot Optionable

Recent News About These Companies

SAB Biotherapeutics (NASDAQ:SABS) Upgraded at Wall Street Zen
SAB Biotherapeutics advances SAB-142 Type 1 diabetes trial
SAB Biotherapeutics Inc SABS
SAB Biotherapeutics Signs Manufacturing Pact for SAB-142

New MarketBeat Followers Over Time

Media Sentiment Over Time

Geron stock logo

Geron NASDAQ:GERN

$1.45 -0.03 (-2.03%)
Closing price 07/28/2026 04:00 PM Eastern
Extended Trading
$1.46 +0.01 (+0.69%)
As of 07/28/2026 04:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Lexicon Pharmaceuticals stock logo

Lexicon Pharmaceuticals NASDAQ:LXRX

$2.34 +0.11 (+4.93%)
Closing price 07/28/2026 04:00 PM Eastern
Extended Trading
$2.31 -0.03 (-1.28%)
As of 07/28/2026 04:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.

OPKO Health stock logo

OPKO Health NASDAQ:OPK

$1.65 +0.41 (+33.06%)
Closing price 07/28/2026 04:00 PM Eastern
Extended Trading
$1.62 -0.03 (-2.00%)
As of 07/28/2026 05:05 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 1991 and is headquartered in Miami, Florida.

SAB Biotherapeutics stock logo

SAB Biotherapeutics NASDAQ:SABS

$3.45 +0.01 (+0.29%)
Closing price 07/28/2026 04:00 PM Eastern
Extended Trading
$3.37 -0.08 (-2.32%)
As of 07/28/2026 04:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.